Corbus Pharmaceuticals Holdings Inc (CRBP)

Corbus Pharmaceuticals Holdings, Inc. stock has experienced significant volatility and a notable decline over the past year, with a 30.13% decrease between November 21, 2024, and November 20, 2025. The stock has seen a decrease of 34.47% over the past year and a 52-week range between $4.64 and $20.56. In March 2025, CRBP stock hit a 52-week low of $5.91. Analyst price targets have ranged from $22.00 to $53.00, suggesting potential upside. Upcoming data readouts for its clinical programs, including Phase 1/2 dose expansion data for CRB-701 at ESMO 2025 and SAD/MAD data for CRB-913 later in 2025, are anticipated as key catalysts. In June 2025, the company initiated the multiple ascending dose (MAD) portion of its Phase 1 study for CRB-913 and was dropped from the Russell 2500 Index.

As a clinical-stage pharmaceutical company, Corbus Pharmaceuticals Holdings, Inc. is primarily focused on the research, development, and clinical trials of its product candidates rather than commercial sales. Therefore, traditional demand seasonality for its products and services is not applicable. The company's revenue generation is primarily through licensing agreements, milestone payments, and potential future product sales once regulatory approvals are obtained.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on oncology and obesity, developing innovative scientific approaches for serious illnesses. The company operates in the Biotechnology and Pharmaceutical Preparations industry. Its pipeline includes CRB-701, a next-generation antibody drug conjugate for solid tumors currently in Phase 1/2 trials; CRB-601, an anti-integrin monoclonal antibody for solid tumors; and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity. Previously, Corbus focused on therapeutics for rare, fibrotic, and inflammatory diseases, with lenabasum as its flagship product candidate.

Corbus Pharmaceuticals Holdings, Inc. is headquartered in Norwood, Massachusetts, United States. The company primarily serves patients in North America and Europe through its clinical trial network.

Corbus Pharmaceuticals Holdings, Inc. has a "Moderate Buy" consensus rating from analysts, with strong analyst interest demonstrated by 6 research reports in the past 90 days. Analysts have provided price targets with significant upside potential, ranging from $22.00 to $53.00. William Blair initiated coverage with an "Outperform" rating, highlighting the potential of CRB-701, and H.C. Wainwright also maintained a "Buy" rating, noting the promise of CRB-701. The significant decline in stock price could negatively impact investor perception, while positive clinical trial updates and presentations have contributed positively to its scientific and development reputation. The appointment of Ian Hodgson as the new Chief Operating Officer in March 2025 also represents a positive corporate development.

Corbus Pharmaceuticals Holdings, Inc. has a mixed ownership structure, with institutional shareholders owning approximately 40.72% to 64.64% of the company's stock, insiders holding around 3.60% to 72.64% of the shares, and retail investors holding approximately 0.00% to 47.08%. Major institutional owners include Cormorant Asset Management, LP, Orbimed Advisors LLC, and Vanguard Group Inc. Sumner Burstein is the largest individual shareholder, owning 3.59 million shares, representing 20.48% of the company.